The Myocet/Lapatinib Study. ICORG 10-03, V5

NCT01495884 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

NETWORK

Sponsor class

Stopped Slower than anticipated accrual

Conditions

Her2 Positive Metastatic Breast Cancer

Interventions

DRUG: non-pegylated liposomal doxorubicon (Myocet™)
DRUG: Lapatinib (Tyverb™)

Sponsor

Cancer Trials Ireland